CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Exelixis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Exelixis Inc
1851 Harbor Bay Parkway
Phone: (650) 837-7000p:650 837-7000 ALAMEDA, CA  94502  United States Ticker: EXELEXEL
Business Summary
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/29/202312/29/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board, Co-Founder Stelios B.Papadopoulos 74 1/1/1998 12/1/1994
President, Chief Executive Officer, Director Michael M.Morrissey 62 7/15/2010 2/1/2000
Chief Financial Officer, Executive Vice President Christopher J.Senner 55 7/15/2015 7/15/2015
9 additional Officers and Directors records available in full report.

Business Names
Business Name
EXEL
Exelixis International (Bermuda) Ltd.
Exelixis Patent Company, LLC
Exelixis Plant Sciences, Inc.
Exelixis U.S., LLC

General Information
Number of Employees: 1,310 (As of 12/29/2023)
Outstanding Shares: 303,194,259 (As of 1/29/2024)
Shareholders: 333
Stock Exchange: NASD
Federal Tax Id: 043257395
Fax Number: (650) 837-8300
Email Address: info@exelixis.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024